This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Global Metabolomics Market Worth $1.5 Billion By 2017

DALLAS, January 11, 2013 /PRNewswire/ --

The report "Metabolomics (Biomarker Discovery/Metabolite Detection/Metabolite Profiling) Market By Applications (Drug Discovery/Toxicology Assessment/ Diagnosis) and Indications (Oncology/Cardiology/Neurology)  -  Forecasts from 2012 to 2017" , analyses the global metabolomics market by region, applications and indications with five year revenue forecasts. It also identifies the factors driving and restraining the global metabolomics market with analysis of trends, opportunities and challenges.

The market is segmented and the revenue is forecasted on the basis of major regions such as America, Europe, Asia and Rest of the World (ROW) covering the key countries for each region. Further, the market is also segmented and revenues are forecasted on the basis of applications and disease indications.

Browse   11 market data tables and 36 figures spread through 136 slides and in-depth TOC on "Metabolomics (Biomarker Discovery/Metabolite Detection/Metabolite Profiling) Market By Applications (Drug Discovery/Toxicology Assessment/ Diagnosis) and Indications (Oncology/Cardiology/Neurology)   - Forecasts from 2012 to 2017" http://www.marketsandmarkets.com/Market-Reports/metabolomics-technology-market-900.html Early buyers will receive 10% customization on reports.

In the post genomic era, metabolomics is gaining importance as another promising "omic" technology for understanding the biology of various diseases. Rapid advancement has been occurring in prediction, detection, monitoring and understanding of various diseases using metabolomic technologies.

The market for metabolomic data analysis tools and software is increasing at a higher rate. Metabolomics allows pharma companies to stretch their R&D efforts by improving efficiency in target discovery and validation, mode-of-action, and toxicology studies. There has been a significant global growth in biotechnology and pharmaceutical industries in the last decade and the market is expected to have a double-digit growth rate in the coming years.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,565.95 -117.63 -0.67%
S&P 500 2,056.01 -12.75 -0.62%
NASDAQ 4,929.8480 -62.0920 -1.24%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs